Top Story

Long-term bariatric surgery outcomes favorable in severe obesity

September 20, 2017

Among adults with severe obesity, those who receive Roux-en-Y gastric bypass are more likely to sustain their weight loss and remain in remission for type 2 diabetes and hypertension compared with those who do not undergo surgery, according to findings published in The New England Journal of Medicine.

Ted D. Adams, PhD, MPH, of the Intermountain Live Well Center Salt Lake, Intermountain Healthcare and the division of cardiovascular genetics, department of internal medicine at the University of Utah School of Medicine in Salt Lake City, and colleagues evaluated data from an observational, prospective study initiated in July 2001 on adults with severe obesity who sought and underwent Roux-en-Y gastric bypass (RYGB; n = 418), sought but did not undergo RYGB (n = 417) and did not seek RYGB (n = 321) to determine weight and metabolic outcomes after 12 years. Participants were followed until March 2016.

More Democrats than Republicans OK with how media covers science

September 20, 2017
More Democrats than Republicans think the news media does a good job of covering science, according to the results of a new study. The Pew Research Center polled more…
In the Journals Plus

Oral glucose tolerance test predicts diabetes risk in relatives

September 20, 2017
Glycemic response to an oral glucose tolerance test may predict the development of diabetes in close relatives of patients with type 2 diabetes, researchers in Iran

AMA urges Senate to reject Graham-Cassidy proposal

September 20, 2017
The AMA recently sent a letter to Senate Majority Leader Mitch McConnell and Minority Leader Charles Schumer strongly opposing the Graham-Cassidy legislation…
Meeting News

Hypocalcemia risk comparable between denosumab, oral bisphosphonate

September 20, 2017
Incidence rates of hypocalcemia in women with postmenopausal osteoporosis are comparable between those treated with denosumab or bisphosphonate monotherapy and the rate…
More Headlines »

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Meeting News

VIDEO: Discussion on diabetes drugs, CV outcomes fruitful

July 17, 2017
More »
Resource Centers

The Future of the Lipid Panel: An NLA Expert Discussion

This educational activity is supported by an educational grant from Quest Diagnostics, Inc.

Past-President of the National Lipid Association and Editor-in-Chief of the Journal of Clinical Lipidology, Dr. W…
More »
Current Issues
View the Current Issue